A 4-fold difference in complete remission rates — 50% versus 12.5% — depending solely on which donor supplied the NK cells is not a minor manufacturing footnote. It is the central biological fact reshaping SENTI-202’s entire registrational trajectory, and it raises an uncomfortable question the Phase 1 data now forces into the open: how much of the variability seen in early CAR-NK trials across the field reflects uncharacterized donor biology rather than construct design?
Senti Bio‘s retrospective covariate analysis of its 22-patient Phase 1 dataset identified a specific NK cell donor phenotype — labeled “Donor X,” deliberately undisclosed — that correlates with markedly superior efficacy. Among the 14 patients who received at least some Donor X-derived SENTI-202 in Cycle 1, the composite complete remission rate hit 50% with 57% ORR; the eight patients receiving non-Donor X material achieved 12.5% cCR and 25% ORR. Preclinical MV4-11 NSG mouse survival data, analyzed post-hoc, confirmed the same directionality. The Donor X phenotype appears in roughly half of adult donors, is independent of HLA or KIR matching, and is associated with published evidence of heightened NK cytotoxicity. Senti is locking all future manufacturing — including pivotal supply — to Donor X material, which simultaneously tightens the product specification and narrows the donor pool by half.
The FDA’s Type B RMAT meeting endorsed a single-arm, multi-center registrational design in relapsed/refractory AML patients consistent with the Phase 1 population. That alignment matters enormously: a single-arm path in R/R AML requires a convincing complete remission rate with durability data to anchor the benefit-risk argument, and Senti has something credible to bring. All CR and CRh responders who were in remission at the 2025 ASH data cut remain in remission with seven additional months of follow-up, the longest ongoing response now exceeding 21 months. In a disease where median survival after second relapse is measured in weeks, that durability is the actual clinical story — not the response rate headline.
The pivotal design detail that will determine whether this program reaches approval is the response rate threshold FDA accepts as the single-arm benchmark. With Donor X-only manufacturing now standardized, Senti’s pivotal cCR rate needs to hold at or near that 50% signal in a broader, multi-site patient population — the moment that number compresses under real-world enrollment conditions is when the single-arm gamble either pays off or forces renegotiation of the entire registration strategy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
